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ABSTRACT 
MICROFLUIDIC CELL SORTING TECHNIQUES TO STUDY DISEASE PROCESSES 
William Neil White 
August 6, 2009 
Circulating nucleated cell populations found in whole blood, including both white blood cells 
(leukocytes) and endothelial cells, provide an ideal platform for studies seeking to understand 
the disease processes for development of drugs and treatments. This thesis presents an 
automated microfluidic device developed for leukocyte enrichment from peripheral blood. 
Briefly, the device allows for complete lysis of red blood cells and comprehensive analysis of 
nucleated cell populations in terms of quantity and activation status. The microfluidic lysis 
device was used in two Sickle Cell disease (SCD) studies to understand the eftect of 
leukocytes in the initiation of vasoocclusivc crisis. Findings suggest abnormally high 
baseline leukocyte counts and variance in clinical expression among SCD patients. Hence, a 
highly favorable state for an inflammatory reaction that may lead to vasoocclusive episodes 
exists. To ascertain risk factors in such incidents revision of current SeD patient 
classification is needed. 
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CHAPTER I - INTRODUCTION 
1.1 MICROFLUIDICS 
Microfluidics has been defined by George M. Whitesides [I] as the SCIence and 
technology of systems that process or manipulate small (10-9 to 10-8 liters) amounts of 
fluids, using channels with dimensions of tens to hundreds of micrometers. Emergence of 
this distinct field was inspired by four disciplines: molecular analysis, biodefense, 
molecular biology and microelectronics. With origins in analysis, success with 
transforming analytical methods such as gas-phase chromatography and capillary 
electrophoresis to the microscale by capillary format influenced other applications of 
microfluidics. A primary stimulus for sudden growth of the micro fluidic field came in the 
1990s with the US Department of Defense developing small-scale systems to detect 
chemical and biological threats. Molecular biology acted as a third motivational source 
with the wave of genomics because of the need for high-throughput analysis with greater 
sensitivity and resolution. Application of fabrication techniques such as photolithography 
from silicon microelectronics and microelectromechanical systems (MEMS), 
nonetheless, has been the most essential for the development of micro fluidic 
technologies. Because of the material restraints of silicon, steel and glass with biological 
samples due to gas permeability, these fabrication techniques were not directly applicable 
at first; although, such materials are now used to build specialized system that require 
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thermal or magnetic support. Hence, an optically transparent, soft and biologically-
friendly elastomer known as poly(dimethylsiloxane), or PDMS, was developed. 
Properties of PDMS make it a suitable platform for miniaturized biological studies. Soft 
lithographic techniques are used to fabricate PDMS devices that are capable of 
controlling fluid flow in molded microchannels for a variety of purposes: immunoassays, 
separation of proteins and DNA, formation of molecular gradients and sorting of cells. 
Common methods for sorting or enriching cell populations on the micro scale include 
magnetic filtration, fluorescent activated cell sorter (F ACS), hydrodynamics and inertial 
focusing [2]. The PDMS microfluidic lysis device described in this thesis is a nucleated 
cell enrichment device that takes advantage of the ability to manipulate cells in a 
microfluidic system to expose whole blood to hypotonic conditions for a controlled 
amount of time in a constant environment. 
1.2 SCALING EFFECTS 
Although the study of fluid mechanics is an old discipline, interest has only moved 
toward fluids on a smaller scale in the past decades. In this realm fluids behavior is 
significantly different as the forces that act on the macroscale become negligent on the 
micro scale and vice versa, phenomena due to scaling effects. The concept of scaling 
expresses variation of physical quantities of a given object or system with respect to size, 
while keeping other quantities (time, pressure, temperature) constant. Applying this to 
dimensionless parameters that convey the quality of tluid flow reveals the dominating 
physical quantities of the microscale. Dimensionless fluidic numbers include Reynolds 
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(inertia -:-- viscosity), Knudsen (molecular spacing -:-- length scale), Peclet (convection -:--
diffusion) and Weber (inertia -:-- surface force); indicating laminar flow (low Reynolds 
number) and domination by molecules, diffusion over convection, and surface forces 
over volume effects as the dimensions get smaller [3]. Harnessing these forces allows 
design of unique devices for research or technical use. 
1.3 THE MICROFLUIDIC ADV ANT AGE 
Interest in the field of micro fluidics has become so large because of the umque 
advantages that working on such a small scale provides. Apparent reasons for 
miniaturization are small device size and minute sample or reagent volumes. Shrinking 
the size of a device enables or enhances characteristics, portability and placement in 
constrained areas, as well as the ability for mass fabrication. Use of small amounts of 
reagents reduces assay costs and extends limited samples. Microfluidic technologies also 
allow for the control of precise geometry of microstructures and constrained geometries 
to confine molecules or mechanical forces, by means of microfabrication. Less obvious 
benefits of miniaturization include increase in the ratio of surface area relative to volume 
and high throughput devices operating through parallel arrays. High-aspect ratio and 
increased throughput lead to more rapid and sensitive analysis. 
1.3.1 CONVENTIONAL ENRICHMENT TECHNIQUES 
Interrogating the immune status of an individual in terms of circulating nucleated cells 
generates important information on condition of health and may help to diagnose disease. 
Accessing these nucleated cell populations through blood sample collection is easier and 
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more convenient than human expressIOn analyses involving tumor tissues. Contained 
within these nucleated cells is essential genetic (DNA) and gene expression (RNA and 
protein) data. Phenotype or activation molecules expressed on the cell membrane also 
bear significance. To examine these nucleated cells in circulation, such as white blood 
cells (leukocytes), one must be able to enrich or sort the populations from other blood 
components, including red blood cells (erythrocytes), and then isolate nucleic acids from 
the cells of interest. Eliminating erythrocytes, which contain little genetic information, is 
relevant as whole blood is composed of 45 % red blood cells, whereas leukocytes only 
make up 1 %. 
Ideally, sample prcparation in terms of sorting or enrichment takes advantage of certain 
cell properties. Conventional techniques sort blood leukocytes by impedance using flow 
cytometry and enrich cells by density and osmotic properties using Ficol density gradient 
separation and ammonium chloride lysis. However, maintaining a constant environment 
for all cells and controlling exposure time to harsh conditions with these techniques is not 
plausible. Because of the lack of sensitivity, cells and even certain populations are lost. 
Furthermore, conventional techniques activate the cells and alter the cellular phenotype, 
resulting in artifactual gene expression [4-6]. Hence, it is often impossible to directly 
compare gene expression data obtained with conventional sample preparation techniques. 
Additionally, protocols for conventional sample preparation techniques also vary 
extensively between laboratories, another source of degradation in the value of the gene 
expression data. 
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Microarray technologies, employed to analyze gene expression data, are powerful and 
widely-used tools for the simultaneous measurement of mRNA abundance of thousands 
of genes. Despite considerable development, widespread use has been limited in clinical 
medicine due to analytical complexities. In a recent report, Irizarray et al [7] 
demonstrated significant variance in microarray analyses from different laboratories 
using the same analytical platforms. The variance could be minimized and consistent 
results obtained if the 'laboratory effect', or protocol variability, was eliminated. Weis et 
al [8] also examined sources of error and variance in gene expression data from different 
laboratories and platforms, and found that results were comparable when common 
platforms and procedures were employed. Such reports stress the need for uniformity in 
protocols and reduction of analytical variance by appropriate standardization. 
1.3.2 ADDRESSING FLAWS IN CONVENTIONAL TECHNIQUES 
Comparative functional genomics using high throughput microarrays provides an 
unbiased platform for genome-wide transcriptome analysis to identify differences in gene 
expression between a control group and well-defined patient populations. Blood 
leukocytes provide an ideal sample for such studies. Enrichment of leukocytes from 
blood without loss or artifactual activation is critical to gene expression profiling. 
Currently leukocyte enrichment protocols are not automated, involve several user-
mediated steps and are associated with cell loss and artifactual Rctivation. Hence arises 
the importance of sample preparation. The micro fluidic protocol introduced in this thesis 
addresses the flaws associated with conventional leukocyte enrichment techniques and 
exhibits relevance to clinical use through studies with Sickle cell disease (SeD) patients. 
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1.4 OUTLINE OF THESIS 
Microfluidics continues to revolutionize the medical field with developments that are 
able to encompass an entire bioi chemical laboratory on the surface of a polymer based or 
silicon chip. This thesis reports the use of microfluidics for applications in the biomedical 
field. In particular, this paper addresses the variance among conventional enrichment 
techniques affecting gene expression data and introduces an automated microfluidic 
platform for clinical studies of disease processes. 
Chapter two illustrates the microfluidic lysis device. The chapter begins with the theory 
behind the device and the mechanism of cell lysis. Subsequent sections of the chapter 
describe the microfabrication of the silicon master mold of the device and how the device 
is prepared from a polymer using soft lithographic techniques. A thorough protocol for 
running the microfluidic device and the unknown cell populations recovered using this 
procedure wrap up the chapter. 
Chapter three discusses aspects of Sickle cell disease (SCD), the disease process 
examined in this thesis. The classical view of SCD, focusing on the genetics of red blood 
cells (RBCs), is introduced, along with new studies looking at white blood cells (WBCs) 
in the pathogenesis of SCD, the onset of a vasoocclusive crisis in the case of this 
disorder. Functions of both RBCs and WBCs in the body are also presented, along with 
descriptions of phenotype and activation markers used to investigate SCD. Section three 
of this chapter states the difference between the populations analyzed in the two studies 
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(Chapters 4 and 5) in this thesis and explores current treatments offered to patients in 
cnsls. 
Chapter four describes the first study of the thesis analyzing conventional techniques and 
the microfluidic lysis protocol using healthy controls and mild phenotype SCD patients. 
After an initial comparison of the conventional and micro fluidic protocols, a 
comprehensive study between healthy controls and mild phenotype SCD patients 
utilizing only the micro fluidic device is presented. Methods, materials, results and a brief 
discussion are included, along with an introduction and motivation for the study. 
Chapter five explains the second study of the thesis seeking to compare mild phenotype 
versus symptomatic SCD patients. In this analysis only microtluidics is used to acquire 
data. Layout of the chapter is similar to that of chapter 4. 
Chapters six and seven provide the conclusions drawn from this thesis study and possible 
future directions for further examinations. 
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CHAPTER II - THE MICROFLUIDIC LYSIS DEVICE 
2.1 THEORY AND MECHANISM 
An automated microfluidic lysis protocol has been developed to accomplish enrichment 
of leukocytes and other circulating nucleated cells without loss or artifactual activation. 
The device (Figure 1) allows for whole blood to rapidly mix with deionized water for ~ 
10 seconds in a 50 ~m x 150 ~m cross-section microfluidic channel of length 128 cm. 
Inlet: Deionize 
water 
Inlet: 2X Phoephate 
buffered •• line 
3.5 em 
Figure 1. Detailed schematic of microfluidics lysis device. 
Whole blood and deionized water are simultaneously introduced into the device via their 
respective inlets to achieve a 1 :30 blood-to-deionized water ratio, which produces 
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complete erythrocyte lysis within lOs. Flow rates of each solution (section 2.4) and total 
volume determine cell exposure time. Due to a low Reynolds number laminar flow exists 
in the microchannels, with diffusion acting as the dominating mixing force. Diffusion of 
deionized water occurs on this level rather quickly, but cells take longer to spread evenly 
throughout the channel and reach an equilibrium condition. Hence, double herringbone 
structures on the bottom of the channel (Figure 2) ensure chaotic mixing and that all cells 
are exposed to the same hypotonic conditions within the device. Characterized by 
Stroock et al [9], the herringbone structures lie in a staggered formation on the bottom of 
the channel and generate several pairs of counterrotating helical flows, which break up 
and mix at each transition between groove patterns. Due to a high surface-area-to-volume 
ratio these helical flows form rapidly in the channels as flowing particles make more 
contact with the channel walls after rising upon contact with the grooves. Cells exposed 
to hypotonic conditions in the channel allow water to cross the plasma membrane through 
osmosis and eventually lyse due to hydrostatic pressure. Due to the comparative small 
size, red blood cells lyse first, whereas more robust white blood cells withstand such 
conditions longer. With a short, controlled exposure time to hypotonic conditions, 
unwanted cell populations can be removed. After exposure to harsh conditions unlysed 
cells are returned to isotonic conditions at the exit of the device and fixed using 2% 
paraformaldehyde. The samples and reagents are automatically metered out in precise 
predetermined volumes, and the constant flow conditions prevent sedimentation or cell 
loss in the micro-channels. Complete and rapid mixing of the cells with the lysis buffer 
streams were visually confirmed by microscopy (Figure 2). 
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Inlet: 
Whole Blood 
eionized 
Water 
Double Herringbone Structure 
r -
Outlet: 
Leukocytes 
t 
• 2XPBS 2XPBS i 
"" Erythrocyte J depleted 
blOOd 
Figure 2. Microscope images of the device at the inlet, herringbone structures in the 
serpentine channels and outlet. 
2.2 MICROFABRICATION 
A silicon mold of the microfluidic device was fabricated usmg photolithographic 
techniques with the equipment in the University of Louisville c\eanroom. To create 
negative replicas of the channels, AutoCAD (Autodesk, Inc. , San Rafael, CA) was used 
to generate a transparency mask (Fineline Imaging, Colorado Springs, CO). The silicon 
wafer was treated with oxygen plasma in an asher (March Instruments, Concord, MA) for 
five minutes (100 mTorr pressure, 100 mV power, 10 % O2 concentration) and spin 
coated with negative photoresist SU-8 (MicroChem, Newton, MA). After a soft exposure 
bake (SEB) the silicon wafer was exposed to UV light using the AB-M mask aligner 
(ABM, Inc., Scotts Valley, CA) followed by a post exposure bake (PEB). Finally the 
silicon wafer was developed in BTS-220 (VWR International, LLC) to rid of uncross-
linked photoresist and flood exposed to UV light for 60 seconds. These processes were 
performed twice as the microfluidic lysis device is a two layer device: channels and 
ridges. SU-8 100 and SU-8 50 were used to create channels and ridges of heights 25 11m 
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and 150 ~m. Parameters for SU-8 100/50 to obtain these channel heights are: Spread 
500/500 RPM (ramp 10011 00), Spin 2000/4000 RPM for 15 seconds (ramp 50011 000), 
SEB 70/20 minutes at 115 C, Expose 61/17 seconds, PEB 13/5 minutes at 115 C, 
Develop 15/5 minutes. To determine correct spin and spread speeds, baking times, UV 
exposure (based upon wavelength absorbance and exposure energy to film thickness) and 
developing times, guidelines were generally followed from the MicroChem data sheets 
on SU-8 50-100 (http://www.microchem.com/products/pdf/SU8_50-100.pdf). 
The micro fluidics device was fabricated usmg soft lithographic techniques. The 
elastomer poly(dimethylsiloxane) (PDMS; Dow Coming, Midland, MI) was mixed 10:1 
with a cross-linker, poured on top the silicon wafer, and cured at 60 C for 12 h. The 
elastomer with the replicated channels was released, and channel access holes were 
punched with a 22-gauge needle. The PDMS wafer was irreversibly bonded to a glass 
slide via oxygen plasma (100 mTorr pressure, 100 mV power, 10 % O2 concentration) for 
one minute. Access tubing (Tygon; Miami Lakes, Fl) of slightly larger diameter was 
press-fitted into the holes. Macro to micro interface is provided through a IS-gauge 
syring needle tip (Microparts Inc., Eagan, MN), attached to the tubing on each of the 
inlets. 
2.3 PROTOCOL FOR RUNNING LYSIS DEVICE 
After the microfluidic device has been fabricated and tested, experiments with 
erythrocyte lysis are ready to begin. The following section details the modified protocol 
for the microfluidic device. 
11 
2.3.1 SAMPLE COLLECTION 
• Collect 4 milliliters of blood sample from median cubital vein, on the anterior 
forearm vein of patient with heparin as anticoagulant in two 2 ml green top 
vaccutainers. 
• Discard first 2 ml tube as it contains dislodged mature endothelial cells (false 
positives). 
• Resuspend the second tube to mix heparin with blood; save immediately on ice. 
• Process the blood sample immediately (within one hour of collection). 
2.3.2 PRIME MICROFLUIDIC DEVICE WITH PBS 
• Fill a I ml syringe with IX PBS and make sure to get rid of bubbles. Connect the 
PBS-loaded 1 ml syringe to inlet 1 (Figure 3) on the microfluidic device. Push 
the syringe containing the IX PBS gently by hand until the solution flows out of 
inlet 2, and then immediately clamp inlet 2 with a standard office binder clip 
• Continue pushing the 1 X PBS until fluid reaches the outlet port of the 
microfluidics device. Once the solution flows out of the outlet, clamp the outlet 
tubing with another binder clip. 
• Continue pushing the I ml syringe until the IX PBS flows out of inlet 3, and 
clamp the inlet 3 port with another office binder clip. The microfluidics device is 
now fully primed. 
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Inle! 1 
(1X PBS/Sample) 
Inlet 2 
(Deionized water) 
Figure 3. Schematic of device showing inlets for respective solutions and outlet. 
2.3.3 PREPARATION OF SYRINGE PUMPS AND SOLUTION 
• To calibrate the pumps follow these steps: 
o For the large Harvard syringe pump (Harvard, PHD 22/2000 Part # 
702001): Set the diameter configuration to 22.5 mm, flow rate 600 flllmin. 
o For the small Harvard Syringe pump (Harvard, PHD 22/2000 Part # 
702209): Set the diameter configuration to 4.61 mm, flow rate 20 flllmin. 
• Fill one 30 ml syringe with sterile deionized water. This can be accomplished by 
withdrawing the solution directly from the 50 ml conical tube. (Label the syringe) 
• Fill a second 30 ml syringe with 2X phosphate-buffered-saline (PBS), 2% 
paraformaldehyde (PF A) using the procedure outlined in step 9. (Label the 
syringe) 
• Fill a 1 ml syringe with IX PBS from the aliquots stored in the 4 ml Falcon tubes, 
using the procedure outlined in step 9. 
• Remove the clamps and connect the 30 ml deionized water syringe to inlet 2 and 
the 30 ml 2X PBS syringe to inlet 3 (make sure you don't trap bubbles in the 
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tubing or microfluidics device). Remove the clamp from the outlet tubing. 
Connect the lX PBS 1 ml syringe into inlet 1. 
2.3.4 ERYTHROCYTE LYSIS 
• Set all of the syringes on the proper Harvard pumps as outlined below: 
o Set the two 30 ml syringes (one containing sterile, de-ionized water and 
the other with 2X PBS, 2% PF A) together on the large Harvard syringe 
pump. 
o Set the 1 ml syringe (containing lX PBS) on the small Harvard syringe 
pump. 
o Place the outlet tubing in a waste collector (50 ml conical tube that is 
labeled "waste"). 
• Tum on the large Harvard syringe pump (with the 30 ml syringes) and let it run 
for one minute. (Make sure there is no leakage in the device or in the tubing). 
• Tum on the small Harvard syringe pump and let it run for an additional mmute. 
(Make sure there is no leakage in the device or in the tubing). Stop the pumps. 
The microfluidics device is now ready to be used. 
• Remove the 1 mI syringe containing IX PBS from the small Harvard syringe 
pump. 
• After obtaining a blood sample, fill the 1 mI syringe with 0.05 ml of sterile IX 
PBS without trapping any bubbles. Next, fill the syringe with 0.5 mls of blood 
obtained from the Eppendorf tube. (The 1 ml syringe will now contain a final 
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volume of 0.55 mls of the blood and IX PBS buffer.) Note: Keep the syringe 
vertical while filling to avoid mixing of the 0.05 ml PBS with the blood. 
• Connect the syringe containing the blood to inlet 1 and mount the synnge 
carefully (avoid pushing the blood through the tubing into the device) on the 
small Harvard syringe pump (the syringe is mounted vertical into the pump). 
• Remove the outlet tubing from the "waste" tube and put a clean 50 ml centrifuge 
tube in its place and set it on a bucket of ice. 
• Switch on the large Harvard syringe pump first and let it run for I minute. Start 
c?llecting the_ sample from the outlet into the 50 ml centrifuge tube 
• Switch on the small Harvard syringe pump. 
• Once the blood sample in the 1 ml syringe has completely traveled through the 
device, stop both pumps. This should take approximately 20 minutes. 
• 
• 
• 
• 
• 
Centrifuge the collected sample for 5 minutes at 350 x g at room temperature with 
the brake off. 
Remove supernatant by placing pipette tip at the opposite side of the white pellet. 
Remove as much supernatant as possible, especially red cell debris, without 
disturbing the white pellet. 
Resuspend the sample in 1 ml of flow buffer. 
F or sample analysis using flow cytometry, add 100 l.d of sample to a flow 
cytometry tube. 
To the 100 f.!l of sample add specified antibody. 
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• Allow sample to incubate for 30 minutes at 40 C. Wash twice with flow buffer 
prior to flow cytometry (add 250 JlI of flow buffer, vortex, spin at 350 g for 5 
minutes, resuspend in 250 JlI of flow buffer). 
2.4 ENABLING ANALYSIS OF UNKNOWN POPULATIONS 
Upon analysis of enriched nucleated cells it is clear that the microfluidic lysis device 
recovers populations of cells lost in conventional techniques (Figure 4a). Figure 4 shows 
flow cytometry scatter plots of nucleated cell populations enriched by different 
techniques grouped into regions by forward scatter (FSC) and side scatter (SSC) light, 
sorting cells based upon size and granulation. Smaller and least granulated cells that fall 
in Region 1 (red) are Lymphocytes. Region 2 (green) consists of larger and semi-
granulated Monocytes. Granulocytes, making up Region 3 (blue), are medium-sized and 
highly-granulated cells. These three regions are the nucleated cells known as leukocytes 
(refer to Section 3.2.2). Cells of interest include those in Region 4 (purple). These 
nucleated populations not salvaged in the conventional techniques Ficol and NH4CL lysis 
(Figure 4b and 4c) are yet to be fully characterized. Preliminary evaluation has revealed 
that this population of unknown cells stains for several antibodies (CD31, CD34, CD36, 
CD61, VEGF R2, CD133, CD138, and CDI46), indicating the presence of multiple cell 
types, including but not limited to progenitor endothelial, mature endothelial, myelocytes, 
reticulocytes, megakaryocytes and other progenitor cells. Note that this may alter the 
population ratio to total nucleated cells that has been determined by conventional 
techniques. However, studies with the microfluidic device include controls to provide 
baseline ratios. 
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(a) (b) (c) 
Figure 4. Comparison of unknown cell populations with different enrichment protocols. 
Region 1 (red) represents Lymphocytes, Region 2 (green) includes Monocytes, Region 3 
(blue) consists of Granulocytes, and Region 4 (purple) contains populations not yet fully 
characterized. 
17 
CHAPTER III - SICKLE CELL DISEASE 
3.1 CLASSICAL VIEW 
Sickle cell disease (SCD) IS a global health problem and the molecular mechanisms 
leading to the manifestation of pain cnSIS and tissue injury are not completely 
understood. The classical view of SCD focuses on the primary genetic defect due to the 
substitution of valine for glutamic acid at the sixth position of the ~-globjn chain that 
produces HbS, which polymerizes when deoxygenated causing it to deform, become rigid 
and obstruct blood flow causing acute and chronic tissue damage. This basic abnormality 
is responsible for the diverse manifestations of sickle cell disease that result in recurrent 
pain and progressive incremental infarction. Hypoxia induces polymerization of sickle 
erythrocytes; however, there is no consensus on the events related to or following 
erythrocyte sickling [10]. 
3~PATHOGENE~SOFSCD 
HbS aggregates distort RBCs and cause them to lose their normal elasticity. Though 
initially a reversible process, repeated episodes of sickling cause RBCs to lose their 
elasticity on reoxygenation causing permanent damage. HbS polymerization and red-cell 
sickling under deoxygenated conditions are central to the pathophysiology of this disease; 
however, growing evidence indicates that SCD is a state of inflammation characterized 
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by vascular endothelium activation and incre~sed blood cell-endothelium interactions 
[11 ]. 
3.2.1 RED BLOOD CELLS AND HEMOGLOBIN 
Red blood cells, or erythrocytes, carry oxygen and carbon dioxide between the lungs and 
the extremities with flow driven by the heart. Erythrocytes are non-nucleated cells with 
little genetic information. Hemoglobin is the protein contained within an erythrocyte that 
oxygen and carbon dioxide molecules bind. Structurally, the normal adult hemoglobin 
protein is made up of two a-chains and two ~-chains forming a quaternary complex. 
http://www.daviddarling. injolimageslhemoglohin jpg 
Figure 5. Structural depiction of hemoglobin chains. 
Conformational changes in the protein occur during transitions from oxygenated to 
deoxygenated states. However, genetic defect in both copies of the ~-globin gene 
(homozygous) leads to the formation of HbS, or sickle hemoglobin, the root of SCD. 
Point mutation in the ~-chain produces a hydrophobic region in the tertiary structure of 
the protein, leading to polymerization and sickling during deoxygenated conditions, 
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becoming irreversible when flexibility is lost and preventing normal conformational 
changes in the protein. These sickle cells initiate and continue to promote vasoocclusive 
crisis, while newly formed red cells are also abnormal. Hence, treatment for the painful 
episode is needed. A mutation in a single allele of the ~-globin gene is known as sickle 
cell trait and does not promote complications of SCD. Rather, sickle cell trait provides for 
a heterozygote advantage to malaria, disrupting parasite incubation in erythrocytes. A 
common therapy in SCD patients is attempt to boost fetal hemoglobin, or HbF, which 
contains y-chains in place of ~-chains, contributing to higher affinity for oxygen 
molecules. 
3.2.2 WHITE BLOOD CELLS 
White blood cells, or leukocytes, are the defenders that compose the immune system. 
Leukocytes, nucleated cells with valuable genetic information, consist of three main 
categories: Granulocytes, Monocytes, and Lymphocytes. Granulocytes are large and 
highly granulated leukocytes that make up the largest population of nucleated cells and 
leukocytes. Categories of Granulocytes include neutrophils, eosoniphils, and basophils. 
Because of their non-specificity in attacking of harmful substances, Granulocytes 
generally arrive first at the scene of a crisis and eliminate threats by phagocytosis. 
Monocytes are large leukocytes that circulate in the blood and mature to macrophages 
upon crossing the endothelium and entering the tissue. These macrophages travel through 
the lymphatic system and alert a specific immune response in the lymph nodes, pancreas 
and spleen. Lymphocytes reside in these areas, smaller leukocytes that attack through 
specific antigens on the membrane surface. Included in the lymphocyte category are T 
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helper (Thl and Th2), Cytotoxic T lymphocytes (CTLs), T regulatory (Treg), Natural 
Killer (NK) and B cells. Figure 6 shows several types of leukocytes. Neither mast cells 
nor platelets are analyzed in the following studies of SCD. Mast cells reside in connective 
tissue and are involved in allergic responses. Platelets are involved in blood clotting and 
are pieces of larger cells called megakaryocytes. 
http://www.gluegrant.org 
Figure 6. Types of leukocytes found in immune system. 
3.2.3 PHENOTYPE AND ACTIVATION MARKERS 
Phenotype and activation markers were selected based on current literature. Both 
phenotype and activation markers are molecules expressed on the membrane surface of 
the respective cell and their presence can be detected by antibody staining. Particular 
phenotype markers are expressed strongly on the respective cell and verify identity. 
Activation markers are expressed based on stimulus and mediate in cell adhesion. Early 
activation markers were used in these studies to elucidate conditions that initiate 
vasoocclusive crisis, and include integrin and selectin molecules. These readily accessible 
proteins subsist in vesicles near the cell membrane and become integrated quickly upon 
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stimulus. In contrast, other activation markers proceed translation based upon gene 
expression response and may take days to appear. Selectins are carbohydrate-binding 
proteins that mediate adhesion of leukocytes to endothelial cells by forming loose bonds 
that allow white blood cells to roll along the endothelium. Integrins, on the other hand, 
are heterodimeric cell surface proteins that mediate adhesion of leukocytes to other 
leukocytes, endothelial cells and extracellular matrix proteins through strong bonds. Also 
spanning the cell membrane, integrins allow communication between the cell and its 
environment. Table I describes phenotype (1 a) and activation (1 b) markers used in the 
following seD studies [12]. 
Table 1 
(a) Description of phenotype markers 
Main Cellular 
Expression 
Endothelial Progenitor 
Endothelia! Mature 
Granulocyte 
Monocyte/Macrophage 
lymphocyte 
leukocyte 
co Phenotype 
Designation 
C0133 
C034 
C061 
C031 
. VEGFR2 
C0138 
C036 
C0146 
C066b 
C014 
C03 
C04 
C025 
C019 
C056 
C045 
Description 
Common EPC marker 
EPe marker; cell-celt adhesion; binds L-selectir: 
Integrin subunit; Forms Ee, WBC, and platelet aggr~gates 
Platelet Endothelial cell adhesion molecule (PECAM-l) 
Vascular Endothelium Grow Factor Receptor 
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EPC marker 
Monocyte/Microvascular EC 
Common endothelium/mature EC marker 
Granulocytes 
Monocytes/Macropnages 
. H{T2 helper cells 
Cytotoxic T Lymphocytes 
T regulatory cell 
B cell 
Natural Killer cell 
leukocyte Comm()11 Antigen 
(b) Description of activation markers 
Main CD 
Cellular 
Expression 
Endothelial 
Mature 
Lymphocyte 
Monocyte & 
Granulocyte 
Activation 
Designation 
CD62P 
CD106 
CD54 
CD69 
CD1a 
CD64 
CD49d 
CD18 
C0162 
CD62L 
CD61 
CDl1b 
HLA-DR 
Description 
P-selectin; Leukocyte adhesion to endothelium via CD162 
Vascular Cell Adhesion Molecule (VCAM-l); ligand fo:- CD49d/CD29 
Intracellular Adhesion Molecule (ICAM-.1); ligand for CDllb/CD18 
Activation Inducer Molecule 
................................ , .. 
Major Histocompatibility Complex (MHC) I-like 
Role in phagocytosis 
Monocyte/T cellintegrin subunit; binds to VCAM 
Granulocyte/Monocyte Integrin subunit; Binds ICAM 
P-selectin a1ycoprotein ligand-l 
L-selectin; Leukocyte-endothelial adhesion 
............................ Integrin subunit 
Granulocyte/Monocyte Integrin subunit; Binds ICAM 
MHC Complex II 
3.2.4 POTENTIAL INTERACTIONS LEADING TO V ASOOCCLUSION 
Patients with SCD have abnormally high baseline leukocyte counts. Severity of SCD 
increases with leukocyte count [11]. Recent in vivo studies suggest that adherent 
leukocytes bind RBCs and contribute to the microvascular pathology that characterizes 
sickle cell disease (SCD), although the precise mechanism is not known. Mice expressing 
the trait for human sickle hemoglobin showed that sickle RBCs bind to adherent 
leukocytes in inflamed venules, contributing to vasoocc1usion [13]. In vivo studies show 
that leukocyte subpopulations from sickle patients capture more RBCs per interacting 
leukocyte than the corresponding subpopulations from healthy controls. All leukocytes 
including lymphocytes, monocytes and neutrophils interact with sickle RBCs [14.1; 
however, neutrophils are thought to contribute the most to vasoocclusive crisis due to 
high numbers in circulation [11]. 
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Leukocyte-RBC interaction is not the cause ofvasoocc1usion, but rather the adherence of 
leukocytes to the endothelium impedes blood flow. Activated leukocytes send signals to 
endothelial cells (ECs), in tum activating the ECs and promoting adherence. Binding of 
monocytes to sickle cells, for instance, activates the vascular endothelium causing 
adhesion and leads to vasoocclusive crises [15]. Leukocyte subpopulations from sickle 
patients are also more adherent to ECs than healthy controls [14]. Transgenic sickle mice 
deficient in P- and E-selectins, which thwart leukocyte adherence to the vessel wall, are 
protected from vasoocclusion [13]. Hence, activation of leukocytes and the endothelium 
plays an important role in SCD. 
3.3 SYMPTOMS AND COMMONLY PRESCRIBED TREATMENTS 
Included in this section are characteristics that classify the three types of patients samples 
used in the studies found in this thesis. Commonly prescribed treatments for seD patients 
with vasoocclusive episodes are also examined. 
3.3.1 CHARACTERISTICS OF PATIENT SAMPLES 
Patients in the clinical studies with the microfluidic lysis device are classified into three 
groups: healthy controls, mild phenotype SCD and symptomatic SCD. Healthy volunteers 
in this study were individuals between the ages of 20 to 60 who have no copy of the allele 
for sickle cell trait. Although using patients with a single copy of the allele may seem 
ideal for healthy controls, obtaming such volunteers is very difficult. In addition, a 
difference in expression of phenotype or activation markers between individuals with no 
copy of the allele and those with two copies is more significant. Mild phenotype SCD 
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.. 
patients, ages 10 to 19, contain both copies of the HbS allele but are not currently 
experiencing any complications of va so occlusive crisis. Symptomatic SCD patients, also 
ages 10 to 19, contain both copies of the HbS allele and are receiving pheresis treatment 
for recurring, painful complications of vasoocc1usive crisis. Blood from these individuals 
was drawn prior to pheresis, with treatment received every 3 to 5 weeks while episodes 
persist. Clinical complications from vasoocclusive crisis include severe pain, acute chest 
syndrome, primary and secondary stroke, priapism and pulmonary hypertension. 
3.3.2 HYDROXYUREA 
One common treatment option for SCD patients includes hydroxyurea. Toxic to 
proliferating, cells, hydroxyurea inhibits the enzyme ribonucleotide reductase from 
producing deoxyribose sugars in DNA [16]. Hence, the drug does not actually decrease 
adhesion of leukocytes to RBCs or ECs by lowering activation markers; rather, 
hydroxyurea prevents occurrences of vasoocclusion by limiting the number of leukocytes 
and RBCs in the blood [17]. Lowering the baseline leukocyte count is critical for 
reduction of crises in SCD. 
3.3.3 PHERESIS 
Pheresis is another commonly prescribed treatment for symptomatic SCD patients. In this 
process blood is removed from the body to filter out particular components by density 
differences. Erythrocytes are exchanged in the case of SCD to rid of sickle cells 
participating in new vasoocclusive events, to provide added oxygen-canying capacity 
2S 
and to decrease blood viscosity. Donor erythrocytes are transfused with other components 
of the blood and returned into circulation. 
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CHAPTER IV - STUDY OF HEALTHY CONTROLS AND MILD PHENOTYPE 
SCD 
4.1 INTRODUCTION 
In thisstudY,,~I~od was sampled from healthy controls (n = 3) and mild phenotype SCD 
patients (n = 3). Each sample was analyzed with micro fluidics, NH4C) mediated lysis and 
Ficol density gradient separation. Once the effectiveness of this device was established in 
a clinical setting as compared to currently available lab techniques, the panel of activation 
markers was expanded and a comparative approach was taken to analyze samples from 
healthy controls (n = 6) and mild phenotype SCD patients (n = 6) using only the 
microfluidic lysis device. Results were published in the journal Biomedical Microdevices 
[18]. 
4.1.1 MOTIVATION FOR STUDY 
This protocol has been validated in the laboratory and pre-clinical settings. However, 
demonstration of the potential of this device to enrich leukocytes in the clinical setting to 
understand disease processes has not been accomplished. In this study the clinical 
effectiveness of the microfluidic protocol to deplete erythrocytes (sickle and nonna]), 
produce high leukocyte yield and minimize artifactual activation was compared to 
conventional techniques using seD as an example. The ability of this protocol to 
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accurately determine leukocyte differential counts and their activation status in mild 
phenotype SCD and healthy controls was verified. 
Several epidemiological studies have implicated abnormally high baseline leukocyte 
counts in SCD patients as a major risk factor in the development of disease related 
complications, with severity increasing with leukocyte count [11]. As a result, the role of 
sickle erythrocytes in SCD has been redefined as an irritant that provokes an 
inflammatory response along with activation of the endothelium [15]. Few studies have 
sought to understand the comprehensive effects of leukocytes and their activation status 
in the initiation of vasoocclusion, and all of these that have utilized conventional 
leukocyte enrichment protocols [19]. Accurately determining leukocyte yield and 
activation within homozygous SCD patients will help in the understanding and treatment 
of this genetic disease. 
4.2 MATERIALS AND METHODS 
This study was done in collaboration with Dr. Ashok Raj and Dr. Salvatore J. Bertolone 
at the center for Pediatric Hematology/Oncology, School of Medicine, University of 
Louisville. Facilities at the Flow Cytometry Core, James Graham Brown Cancer Center, 
University of Louisville were utilized to run samples, assisted by Dr. Sam Wellhausen. 
The following section briefly explains the process by which the experiments were carried 
out during this study. It includes details on patient classifications~ protocols for 
conventional and micro fluidics lysis enrichment techniques and flow cytometry sample 
and data analysis. 
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4.2.1 BLOOD SAMPLES 
Blood collection was approved by the Institutional Review Board of the University of 
Louisville. After obtaining written consent, 4 mL of blood were drawn from a total of 9 
healthy volunteers and 9 mild phenotype SCD patients (n = 3 for initial study and n = 6 
for expanded panel of antibodies) with sodium heparin as anticoagulant (Vacutainer™, 
Becton Dickinson, Franklin Lakes, NJ). 
4.2.2 SAMPLE CLASSIFICATION 
Healthy volunteers in this study were between the ages of 20 to 60, did not have a copy 
of the allele for SCD and were not of any particular race. Mild phenotype SCD patients 
contained copies of both alleles of the sickle cell trait. Patients were of African-American 
descent between the ages of 10 to 19 with no vasoocclusive crisis. Refer to section 3.3 for 
more details on patient sample classification. 
4.2.3 STANDARD NH4CL MEDIATED LYSIS PROTOCOL 
Blood samples were extracted and mixed with erythrocyte lysis buffer (Fischer Scientific, 
Florence, KY) in a ratio of 1: 15 and mixed thoroughly by vortexing for 5 minutes. The 
sample was then spun down in a refrigerated centrifuge at 4°C for 10 minutes at 400g. 
The supernatant was discarded and the pellet was resuspended in flow cytometry buffer 
for further analysis. 
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4.2.4 STANDARD FICOL DENSITY GRADIENT SEPARATION 
1 mL of blood sample was diluted with 2 mL of IX phosphate buffered saline (PBS) and 
then layered gently on top of Ficol density gradient separation medium (GE Healthcare, 
Bio-Sciences AB, Uppsala, Sweden) in a 15 mL conical tube. This was then spun down 
at 500g for 30 minutes in a refrigerated centrifuge at 4°C. The first layer containing· 
platelet rich plasma was discarded, the second layer (white band) containing the 
peripheral blood mononuclear cells (PBMCs) was fractionated, the third layer of Ficol 
solution was discarded and the pellet containing polymorphonuclear cells (PNMs) and 
erythrocytes was enriched and subject to NH4CI mediated lysis protocol for elimination 
of erythrocytes. The PBMCs and PNMs were then combined together in flow cytometry 
buffer for flow cytometric analysis. 
4.2.5 MICROFLUIDIC LEUKOCYTE ENRICHMENT 
A micro fluidic lysis device similar to the device described by Sethu et al [20] was used 
for enrichment of leukocytes and circulating nucleated cells from whole blood. Briefly, 
the device allows for whole blood to rapidly mix with deionized water in a 1 :30 ratio for 
about 10 seconds in a micro fluidic channel, which is sufficient for complete lysis of 
erythrocytes. The remaining cells are returned to isotonic conditions at the exit of the 
device and fixed using 2% paraformaldehyde (PFA). Following centrifugation to remove 
erythrocyte debris, the remaining leukocytes were suspended in a flow buffer containing 
1% bovine serum albumin (BSA), 1% PFA and 0.1% sodium azide for staining and flow 
cytometry. Refer to section 2.4 for an in depth protocol of the microfluidic lysis device. 
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4.2.6 CELL COUNTS AND FLOW CYTOMETRIC ANALYSIS 
For each leukocyte-enriched sample, total cell counts following lysis were obtained using 
a Cellometer™ (Nexce1om, Lawrence, MA), automated cell-counting system. Each 
sample was counted twice and averaged to obtain the total cell counts. Different 
subpopulations were then assessed by flow cytometry. Cells were visualized using 
peridin chlorophyll-a (PerCP), fluorescein isothiocyanate (FITC), phycoerythrin (PE) and 
allophycocyanin (APC) conjugated antibodies (BD Biosciences, San Jose, CA) against 
leukocyte phenotype and activation cell-surface markers (Table 2). Conjugated antibodies 
VEGF R2/KDR (R&D Systems, Minneapolis,MN) and CD133 (Ancell Co., Bayport, 
MN) were also used to visualize endothelial cells. Stained cells were washed in 1 % HAB 
(Hank's balanced salts without calcium or magnesium, plus 1 % bovine serum albumin, 
0.1 % sodium azide, and 1mM ethylenediamine tetraacetic acid), pelleted, resuspended in 
HAB, and analyzed on a F ACSCalibur™ flow cytometer (BD Biosciences, San Jose, 
CA), using CellQuest™ software (BD Pharmingen). Cell activation was scored using the 
Rank Sum Test. All data correspond to the means of cell concentration or fluorescence 
intensity, ± S.E.M., for controls (n = 6) and mild phenotype SCD (n = 6). 
4.2.7 FLOW CYTOMETRY DATA ANALYSIS 
Flow cytometry data files were analyzed using WinMDI software (Scripps Institute, Flow 
Cytometry Core Facility, San Diego, CA). Each data file was manually gated and 
analyzed using different .combinations of phenotype and activation markers. All 
fluorescence expression was normalized using controls and is represented as mean 
fluorescence intensity (MFI) in arbitrary units. 
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Table 2 
Cell Types with corresponding phenotype and activation markers 
Cell Iype Phen,otype Marker 
. . Granulocytes CD66+ 
Granulocyte sub-population CD&6+/CD49d+ 
Monocytes CD14+ 
MonocytesIMacrophages CD36+ 
Myelocytes CD11 b+!CD66+ ICD49d+ 
Th1 and Th2 CD4+!CD3+ 
en CD4-/CD3+ 
B celis· CD~!CD25-lCD56--/CD3-
T-reguJatory,cells .. CD4+ ICD25+ 
Natural Killer cells. CD56+ 
Mature Endothelial ceJJ 
Progenitor Endothelial ceMs 
4.3 RESULTS 
CD146+/CD36+ 
CD146+/CD31+ 
CD133+/CD34+ 
VEFG R2+ 
VEGF R2+!CD34+ 
VEFG R2+!CD133+ 
Cell Type 
Granulocytes 
Monocytes. 
Endothehal GeNs' 
Activation Marker 
CD18 
CD11b 
CD18 
CD11b 
HLA-DR 
CD1a 
CD62P 
CD106 
CD36 
CDM 
This section summarizes the results comparing the micro fluidics protocol to conventional 
techniques in terms of cell loss and artifactual activation. Comprehensive analysis using 
the microfluidic protocol is also presented. Graphs and tables are provided. 
4.3.1 ERYTHROCYTE DEPLETION AND LEUKOCYTE YIELD 
Blood samples were drawn from healthy controls and mild phenotype SCD patients and 
leukocytes were enriched using micro fluidic lysis, conventional NH4Cl mediated lysis 
and Ficol density gradient separation. Circulating nucleated cells were phenotyped using 
fluorescently labeled antibodies as CD3+CD4+ Thl and Th2, CD3+CD4- CTL, CD19+ 
B cells, CD14+ Monocytes and CD66b+ Granulocytes and evaluated using 4 color flow 
cytometry. Results in actual cell counts per mL of whole blood (Figure 7) indicate that 
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micro fluidic leukocyte enrichment resulted in significantly higher cell yield for all cell 
types in both healthy controls and mild phenotype SCD patient samples. Also, flow 
cytometry confirmed absence of erythrocytes or erythrocyte debris. 
Healthy Controls Mild Phenotype SCD 
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• Microfluidics !:::J Lysis iBl Ficol 
Figure 7. Comparison of leukocyte yield between enrichment techniques. 
4.3.2 LEUKOCYTE ENRICHMENT PROCESS INDUCED ACTIVATION 
Phenotyped leukocytes using each of the aforementioned techniques were evaluated for 
expression of early activation markers. Lymphocytes were not scored for activation as T 
and B Lymphocyte activation typically requires > 24 hours and most enrichment 
protocols last ~ 30-60 minutes. Cells enriched using Ficol density gradient separation 
were also not scored, since Granulocytes enriched via Ficol density gradient separation 
require NH4CI mediated lysis to eliminate contaminating erythrocytes. Therefore we 
compared expression of early activation markers in Monocytes and Granulocytes 
enriched using microfluidics and NH4CI mediated lysis. Monocytes were analyzed for 
expression of integrins CD 11 b and CD 18 and Major Histocompatibility Complex II 
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(HLA-DR) whereas granulocytes were analyzed for expression of integrins CDI! band 
CD18. Results (Table 3) indicate lower expression of early activation markers following 
enrichment with micro fluidics for both healthy controls and mild phenotype SCD 
samples. 
Table 3 
Comparison of activation between enrichment techniques 
Healthy Controls MI d Phenotwe S CD 
Mir;r(lflllidics lysis MlcmOuldlcs L\I$i!li 
MNn SEM· 'Mi,II,'w SfM .wtl.l'l SCM Mool' SEM 
emit 07.82:; 3.14 152.36' 2:1.)1 
CDHb~' 331.!}(: 55.4{· 72tH!) 513.52 
fILA-Oft.. . 2.4ei) (') 3() 2 S-~ 0.32 
CI}U. 
Monocytes 
6.@ 
"',,',,' 
100.72 jfj.f6 134.65 
.%h.141 2.35· 00397 rJ4.513 
227 CUi' 2.4$ 022 
CD6Gb* CD?'., £6.51 4.77 77.82 i3.00 GIQlllllo~.$ GDl1b.· 317.01 110.38. 544.45 i64.oo 48. 74 2.30 65.49 13.00 160.2"1 42.zt. 39>l.fIJ 134.12 
4.3.3 COMPREHENSIVE EVALUATION OF LEUKOCYTE ACTIVATION 
MARKERS IN SCD 
Controls and mild phenotype SCD samples were analyzed comprehensively using the 
microfluidic enrichment protocol. Leukocytes and other circulating nucleated cell 
populations were phenotyped and their counts were determined. Activation markers for 
several leukocyte and circulating endothelial cell populations were also measured. 
Circulating nucleated cells were phenotyped and split into the following panels: 
Lymphoid (Figure 8), Myeloid (Figure 9), Mature Endothelial and Endothelial Progenitor 
(Figure 10). Lymphoid panel included CD3+CD4+ Th 1 and Th2, CD3+CD4- CTL, 
CD4+CD25+ Treg, CD56+ NK and CD4-CD25-CD56-CD3- B cells. Myleoid panel 
consisted of CD66b+ Granulocytes, CD 11 b+CD66b+CD49+ Myelocytes, 
CD66b+CD49+ Granulocyte subpopulation, CD14+ Monocytes and CD36+ 
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MonocyteslMacrophages. Mature Endothelial panel included CDI46+CD36+ and 
CDI46+CD31+. Progenitor Endothelial panels consisted of CDI33+CD34+, VEGF 
R2+CD133+, VEGF R2+ and VEGF R2+CD34+. Expression of activation markers 
(Figure 11) was quantified for CDIIb, CDI8 and HLA-DR on Monocytes, CDllb and 
CDI8 on Granulocytes, CDla on Lymphocytes and ICAM-I (CDS4), VCAM-I 
(CDI06), P-Selectin (CD62p) and CD36 on circulating endothelial cells. 
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Figure 8. Lymphoid panel. 
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Figure 9. Myeloid panel. 
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Figures 8-10 show comparisons of actual cell counts per mL of whole blood in controls 
and mild phenotype SCD patients. From the data it can be seen that the leukocyte 
(lymphoid and myeloid) and circulating endothelial counts (mature and progenitor) are 
higher in mild phenotype SCD patients. There is no selective increase in any sub-
population; rather, there are proportional increases of about 2 fold in all subpopulations. 
Exceptions include B cells, Myelocytes and the Granulcoyte subpopulation where there 
was a 3-4 fold increase. Figure 11 shows the comparison of various activation markers 
between the two groups. Results show that there is no statistically significant increase 
(Rank Sum Test) with a confidence of p = 0.05 in expression of activation markers 
between the groups. 
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Figure II. Activation of nucleated cells. 
4.4 DISCUSSION 
,1 
seD serves as an excellent model to show the superiority of the micro fluidic protocol as 
a sample preparation technique toward clinical studies. Published literature indicates that 
seD patients have abnormally high leukocyte counts in peripheral blood and that 
activation markers are expressed during periods of vasoocclusive crisis. Leukocytes also 
interact with the damaged endothelium layer and may contribute to vasoocclusion [19]. 
With many cell types present in the pathogenesis of SeD, it is important to accurately 
determine those playing a major role. By analyzing the activation status and gene 
expression profile of the circulating cell populations in seD patients, the mechanism of 
vasoocclusion can be realized and treated. Sample preparation technique without cell loss 
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and artifactual activation will therefore have a significant impact on the interpretation of 
the data attained from a study. 
Results comparing the microfluidic protocol to NH4CI mediated lysis and Ficol density· 
gradient separation have been presented. Minimal loss and artifactual activation of 
circulating cell popUlations were exhibited and graphical comparison is shown in Figure 
7 and Table 3, respectively. Microfluidics proved to be superior for use in SeD patients. 
Next the panel was expanded and the microfluidic protocol was used to comprehensively 
profile the circulating cell populations in mild phenotype SCD patients. Markers for 
leukocytes and circulating endothelial cells were obtained from literature as the most 
widely used for each population in terms of phenotype and activation using flow 
cytometry [21-25]. Results from this part of the study indicate that mild phenotype SCD 
patients have a non-selective increase in leukocyte counts as compared to healthy 
controls, as shown in Figures 8 and 9. Increase in mature and progenitor endothelial cells 
was not significant, depicted in Figure 10. The most substantial result, illustrated in 
Figure 11, shows no statistical difference in activation between mild phenotype SCD 
patients and healthy controls. 
Significance of this data can be interpreted in terms of the role of leukocytes in 
vasoocclusive crisis in SCD patients. SCD patients in this study were mild phenotype and 
not in a state of pain crisis. However, leukocyte levels were still elevated compared to 
controls, although not activated. This study therefore provides evidence that leukocytes in 
mild phenotype SCD patients are not in a chronic state of inflammation; rather high 
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leukocyte counts represent a state, highly favorable for development of an inflammatory 
response in reaction to a given stimulus. As for circulating endothelial counts, both 
mature and progenitor endothelial cells were not activated in SCD patients compared to 
controls. Circulating mature endothelial cells were most likely present due to damage and 
displacement from the blood draw or from sickle erythrocytes damaging the endothelium 
layer. Very few, inactivated progenitor endothelial cells were found in circulation. 
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CHAPTER V - STUDY OF MILD PHENOTYPE SCD AND SYMPTOMATIC 
SCD 
5.1 INTRODUCTION 
In this study blood was sampled from mild phenotype (n = 11) and symptomatic seD 
patients (n = 11). Each sample was enriched for nucleated cells using the microfluidic 
lysis device and analyzed using flow cytometry. The panel of activation markers was 
expanded from the previous study. A similar comparative approach was taken to analyze 
samples from mild phenotype and symptomatic SCD patients. 
5.1.1 MOTIVATION FOR STUDY 
Clinical potential of this device to enrich leukocytes and understand disease processes is 
tested. In the previous study a baseline leukocyte count and activation status was set for 
healthy controls and mild phenotype SCD patients [18]. The objective of this study was 
to compare percentage of nucleated cell populations and activation of these populations 
between mild phenotype and symptomatic SCD patients. Using the microfluidic lysis 
device to enrich nucleated cell populations and flow cytometry analysis, a direct 
comparison between the two categories of SCD patients was made to search for a 
possible marker that may indicate and/or playa role in the onset of vasoocclusive crisis. 
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Several studies have been carried out comparing mild phenotype and symptomatic SCD 
patients. With no consensus on the events leading up to a vasoocclusive crisis [10], 
several articles have suggested the importance of epigenetic effects on the mutated ~­
globin gene in SCD that produces extreme variability in clinical expression among 
individuals [14, 26-28], while others have proposed the importance of certain expression 
markers on leukocyte popUlations that may indicate the inevitability of a painful episode 
[13, 15, 19, 29]. By staining for these possibly relative expreSSIOn markers, each 
population of nucleated cells was examined according to phenotype, accomplishing 
enrichment with the micro fluidic lysis device, to determine if a difference in expression 
between groups or individuals exists. Other studies analyzing expression markers utilized 
conventional techniques for enumeration, therefore prone to cell loss and artifactual 
activation, skewing results and deduced conclusions [11]. Hence, clinical expression of 
markers among individuals may be too variable to investigate. Accurately determining 
activation status of nucleated cell populations among mild phenotype and symptomatic 
SCD patients will aid in the comprehension and prevention of vasoocclusive crises. 
5.2 METHODS 
This study was done in collaboration with Dr. Ashok Raj and Dr. Salvatore J. BertoJone 
at the center for Pediatric Hematology/Oncology, School of Medicine, University of 
Louisville. Facilities at the Flow Cytometry Core, James Graham Brown Cancer Center, 
University of Louisville were utilized to run samples, assisted by Dr. Sam Wellhausen. 
The following section briefly explains the process by which the experiments were carried 
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out during this study. It includes patient classifications, protocol for the microfluidic lysis 
enrichment and flow cytometry sample and data analysis. 
5.2.1 BLOOD SAMPLES 
Blood collection was approved by the Institutional Review Board of the University of 
Louisville. After obtaining written consent, 4 mL of blood were drawn from a total of 11 
mild phenotype and 11 symptomatic SeD patients with sodium heparin as anticoagulant 
(Vacutainer™, Becton Dickinson, Franklin Lakes, NJ). 
5.2.2 SAMPLE CLASSIFICATION 
Mild phenotype SeD patients contained copies of both alleles of the sickle cell trait and 
were of African-American descent between the ages of 10 to 19 with no vasoocclusive 
crisis. Symptomatic SeD patients were receiving pheresis treatment for vasoocclusive 
episodes. Refer to section 3.3 for further details on patient sample c1assit'ication. 
5.2.3 MICRO FLUIDIC LEUKOCYTE ENRICHMENT 
A micro fluidic lysis device similar to the device described by Sethu et al [20] was used 
for enrichment of leukocytes and circulating nucleated· cells from whole blood. The 
device allows for whole blood to rapidly mix with deionized water in a 1 :30 ratio for 
approximately 10 seconds. Detailed theory, mechanism and protocol for the device can 
be found in section 2. The remaining cells are returned to isotonic conditions at the exit 
of the device and fixed using 2% parafonnaldehyde (PFA). Following centrifugation to 
remove erythrocyte debris, the remaining leukocytes were suspended in a flow buffer 
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containing 1 % bovine serum albumin (BSA), 1 % PF A and 0.1 % sodium azide for 
staining and flow cytometry. 
5.2.4 FLOW CYTOMETRIC ANALYSIS 
Different subpopulations were assessed by flow cytometry. Cells were visualized using 
peri din chlorophyll-a (PerCP), fluorescein isothiocyanate (FITC), phycoerythrin (PE) and 
allophycocyanin (APC) conjugated antibodies (BD Biosciences, San Jose, CA) against 
leukocyte phenotype and activation cell-surface markers. Conjugated antibodies VEGF 
R2/KDR (R&D Systems, Minneapolis, MN) and CD133 (Ancell Co., Bayport, MN) were 
also used to visualize endothelial cells. Refer to Table 4 for list of markers. Stained cells 
were washed in 1 % HAB (Hank's balanced salts without calcium or magnesium, plus 1 % 
bovine serum albumin, 0.1 % sodium azide, and 1 mM ethylenediamine tetraacetic acid), 
pelleted, resuspended in HAB, and analyzed on a F ACSCalibur™ flow cytometer (BD 
Biosciences, San Jose, CA), using CellQuest™ software (BD Pharmingen). Cell 
expression was scored using the Rank Sum Test. All data correspond to the means of 
total percentage of cells or relative high percentage ofregioned populations, ± S.E.M., for 
mild phenotype (n = 11) and symptomatic SCD (n = 11). 
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Table 4 
Nucleated cell populations and corresponding phenotype and activation markers 
Cell Type Phenotype Marker Cell Type Activation Marker 
C034+/CD133+/C061+ C0106 
Endothelial Progenitor C034+/C0133+/C031+ 
Endothelial Mature CD62P 
C034+/C0133+/VEGFR2+ C054 
C034+/C0133+/C0138+ CD64 
Endothelial Mature C0146+/C031+/CD36+ CD49d 
Granulocyte C066b+ Monocyte/Granulocyte C0162 
Monocyte/Macrophage CD14+ CD62l 
C03+/C04+ cow (Mon) 
Lymphocyte C03+/C04- C061 (Gran) 
C025+/C04+ Lymphocyte C069 
WBC C045+ 
5.2.5 FLOW CYTOMETRY DATA ANALYSIS 
Flow cytometry data files were analyzed using WinMDI software (Scripps Institute, Flow 
Cytometry Core Facility, San Diego, CA). Each data file was manually gated and 
analyzed using different combinations of phenotype and activation markers. All 
fluorescence expression was normalized using controls and is represented as a percentage 
of nucleated cells in venous circulation. 
5.3 RESULTS 
This section summarizes the results of the expanded panel of antibodies to study the 
pathogenesis of SCD using the microfluidic protocol. Graphs and tables are provided. 
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5.3.1 ERYTHROCYTE DEPLETION AND LEUKOCYTE YIELD 
Blood samples were drawn from mild phenotype and symptomatic SCD patients and 
leukocytes were enriched using microfluidic lysis. Leukocytes and other circulating 
nucleated cell populations were phenotyped and their percentages were determined. 
Circulating nucleated cells were phenotyped and split into the following panels: 
Leukocytes (Figure 12) and Endothelial (Figure 13). Leukocytes were phenotyped using 
fluorescently labeled antibodies as CD3+CD4+ Thl and Th2, CD3+CD4- CTL, 
CD4+CD25+ Treg cells, CD 14+ Monocytes, CD66b+ Granulocytes and CD45+ 
Leukocytes. Endothelial panel included Mature Endothelial CD 146+CD36+CD31 + and 
Progenitor Endothelial CDI33+CD34+CD61+, CD 133+CD34+CD31 +, 
CDI33+CD34+CD138+ and CD133+CD34+VEGF R2+. Panels were evaluated using 4 
color flow cytometry. Results in percentage of total nucleated cells (Figures 12-13) 
indicate that no definitive difference can be seen (p 2: 0.05) between mild phenotype and 
symptomatic SCD patients. 
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Figure 12. Leukocyte phenotype panel. 
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Endothelial Phenotype 
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Figure 13. Endothelial phenotype panel. 
5.3.2 LEUKOCYTE ACTIVATION MARKERS IN SCD 
Mild phenotype and symptomatic SCD samples were analyzed comprehensively using 
the micro fluidic enrichment protocol. Activation markers for several leukocyte and 
circulating endothelial cell populations were measured. Expression of activation markers 
was quantified for CD64, CD49d, CDI8, CD162 and CD62L on Monocytes (Figure 14), 
CD64, CD49d, CD61, CD162 and CD62L on Granulocytes (Figure 15), CD69 on 
Lymphocytes (Figure 16) and ICAM-l (CD54), VCAM-l (CD106) and P-Selectin 
(CD62p) on circulating Endothelial Cells (Figure 17). 
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Figure 15. Granulocyte activation paneL 
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Figure 17. Endothelial activation panel. 
Figures 12-13 show comparisons of percentage of total nucleated cells in mild phenotype 
and symptomatic seD patients. From the data it can be seen that there is no significance 
between leukocyte (lymphoid and myeloid) and circulating endothelial counts (mature 
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and progenitor). However, there is a large variance among patient samples; hence, Table 
5 depicts percentage of total nucleated cells (Leukocyte and Endothelial) ranging from 
high to low. Figures 14-17 show the comparison of various activation markers between 
the two groups, based on Leukocyte and Endothelial sUbpopulations. Results show that 
there is no statistically significant increase (Rank Sum Test) with a confidence of p ::::: 
0.05 in expression of activation markers between the groups, with the exception of a 
significant difference (Figure 14) of CD62L expression on Monocytes (p < 0.01). Since 
there is still a large variance among patient samples, Table 6 depicts percentage of 
regioned nucleated cell populations (Leukocyte) ranging from high to low. 
Table 5 
Ranked values of percentage of total nucleated cells 
Highest to Lowest Avg SEM 
CD66b+ Symptomatic 70.64 68.85 61.34 56.51 51.59 47.13 45.25 44.27 30.17 29.55 24.22 48.14 4.73 
Mild Phenotype 76.34 67.43 66.12 61.19 57.70 55.85 52.59 46.22 42.40 35.89 34.09 54.17 4.06 
C014+ 
Symptomatic 27.51 19.08 11.14 W.67 8.06 8.02 7.73 6.62 5.31 3.87· 3.00 10.09 2.13 
% 
Mild Phenotype 18.39 17.14 12.49 9.29 6.68 5.62 4.83 2.62 2.60 2.20 1.85 7.61 1.81 
Total CD3+/C04f-
Symptomatic 10.26 7.75 7.33 7.33 6.54 6.30 5.87 5.43 4.46 3.32 2.51 6.10 0.66 
Cells Mild Phenotype 14.87 13.64 12.95 
9.85 8.41 8.22 6.97 5.48 4.75 2.67 2.22 8.19 1.30 
CD3+/C04· 
Symptomatic 9.45 .9.03 6.03 5.99 5.45 5.44 5.35 4.31 3.21 3.07 2.38 5.47 0.66 
Mild Phenotype 13.76 12.59 9.30 9.11 8.15 7.00 6.44 6.14 5.54 3.01 1.95 7.55 1.08 
C025+/C04+ 
Symptomatic 1.43 1.41 1.39 1.36 1.27 1.04 0.98 0.85 0.74 0.65 0.20 1.03 0.12 
Mild Phenotype 4.79 4.16 3.24 1.49 1.83 1.25 0.55 0.51 0.49 0.47 0.22 1.82 0.49 
CD34+/C0133+/ Symptomatic 14.94 10.71 6.81 6.70 4.70 4.30 3.64 3.53 3.08 0.85 0.18 5.40 1.30 
CD61+ Mild Phenotype 17.60 16.n 11.17 6.21 3.22 3.03 2.00 1.70 0.53 0.37 0.27 5.72 1.96 
C034+/COB3+/ Symptomatic 14.97 10.76 6.81 6.73 4.79 4.70 3.69 3.60 3.10 1.15 0.21 5.50 1.28 
... 
C031+ Mild Phenotype 17.59 16.92 11.26 6.75 3.71 3.11 2.37 1.78 0.51 0.38 0.30 5.88 1.95 
% CD34+/C0133+/ Symptomatic 28.82 18.51 9.96 7.40 
7.13 6.48 5.01 4.26 3.50 1.66 1.58 8.57 2.47 
Total 
VEGFR2+ Mild Phenotype 26.55 9.66 9.45 7.93 6.9Q 6.23 6.19 3.84 1.82 0.98 0.34 7.26 2.16 
cells CD34+/C0133+1 Symptomatic 28.82 18.12 9.59 7.11 6.96 6.47 4.97 3.76 3.49 1.51 1.45 8.39 2.47 
C0138+ Mild Phenotype 24.81 9.34 8.99 7.33 5.70 6.19 5.10 3.81 1.97 0.91 0.29 6.95 2.01 
C0146+/CD31+/ Symptomatic 0.85 o.n 0.69 0.46 0.37 0.37 0.36 0.21 0.19 0.12 0.11 0.41 0.08 
C036+ Mild Phenotype 1.39 0.58 0.54 0.49 0.49 0.47 0.37 0.19 {j.18 {j.10 0.09 0.45 0.11 
CD45+ 
Symptomatic 92.27 91.01 89.53 &5.31 81.88 78.50 75.72 74.02 70.90 69.88 67.76 79.71 2.67 
Mild Phenotype 96.43 93.10 92.96 90.34 89.61 79.06 73.90 73.84 72.47 61.89 51.42 80.46 3.83 
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Table 6 
Ranked values of percentage of regioned nucleated cell populations 
Avg SEM 
COM 
Symptomatic 23.18 8.26 7.57 5.56 2.08 1.81 1.74 1 . .59 1.36 0 . .59 0 . .55 4.94 2.00 
Mild Phenotype 17.17 9.26 4.33 2.79 1.83 1.65 0.99 0.64 0.55 0.50 0.45 3.65 1.56 
C061 
Symptomatic. 19.46 19.38 16.38 12.77 11.04 8.05 7.10 4.48 4.17 1.89 1.15 9.62 2.01 
, Mild Phenotype 72.66 40.42 33.69 28.73 16.79 16.16 15.06 12.34 6.98 5.06 4.81 22.97 6.10 
% Symptomatic 99.56 98.82 97.12 97.10 96.34 96.11 95.06 93.92 89.64.85.77.81.71 93.74 1.71 
CD162 
Granulocytes Mild Phenotype 97.99 97.89 96.37 92.85 88.82 86.99 84.32 78.03 72.6.5.60.58. 29.53 80.55' 6.18 
CD62l Symptomatic 
91.18 89.08 88.74 87.79 85.80 &2.89 81.14 77.82 71.75 68.43 50.89 79.59 3.02 
Mild Phenotype 91.04 83.63 82.70 80.41 78.25 69.93 68.88 56.53 52.01 50.92 24.41 67.16 5.90 
CD49d· Symptomatic 27.36 16.35 15.48 13.98 8.18 7.62 6.63 5.37 4.54 4.22 3.59 10.30 2.20 
Mild Phenotype 30.12 16.66 9.40 9.25 9.06 8.46 7.10 6.64 4.27 4.14 3.79 9.90 2.29 
C064 symptomatic 99.35 
99.21 97.73 97.72 97.52 97.45 97.31 96.50\ 96.07 93.12 89.52 96.50 0.86 
Mild Phenotype 99.81 97.98 97.97 97.60 96.41 96.39 94.62 92.91 90.22 89.47 80.37 93.98 1.68 
C018 
Symptomatic. 99.85 99.85 99.64 99.58 99.54 99.30 98.94 98.6.5 9.5.04 94.66 94.22 98.12 0.68 
Mild Phenotype 100.00 99.82 99.61 99.17 98.66 98.50 98.03 97.57 97.14 95.38 94.66 98.05 0.53 
% Monocytes C0162 Symptomatic 100.00 99.82 99.62 99.60 ·99.50 99.39 99.17 98.94 98.46 98.02 94.62 98.83 0.46 
Mild Phenotype 100.00 100.00 99.72 99.61 99.34 98.15 97.94 97.44 97.35 96.66 93.69 98.17 0.57 
C062l 
Symptomatic 91.96 89.26 88.14 87.50 84.6.5 70.93 58.73 56 . .54 40.33 32.11 2.39 63.87 S.78 
Mild Phenotype 69.91 67.04 52.35 35.92 31.13 27.69 26.74 23.48 10.07 2.94 . 2.11 31.76 7.03 
CD49d Symptomatic 98.81 98.02 96.07 93.06 91.63 91.53 91.52 91.23 90.86.85.09 84.73 92.05 1.36 
Mild Phenotype 98,49 98.43 98.28 96.49 94.02 90.51 89.72 84.55 84.22 84.13 83.87 91.16 1.88 
COI06 
Symptomatic 100.00 100.00 99.60 98.47 98.09 97.00 96.30 88.20 85.98 85.71 81.58 93.72 2.08 
Mild Phenotype. 100.00 99.65 94.32 93.81 92.78 91.67 90.98 83.27 82.81 82.68 71.43 89.40 2.57 
% Endothelial symptomatic 100.00 100.00 9955 99.45 98.94 98.25 98.13 97.23 93.79 89.47 80.95 95.98 1.78 
C062P 
Cells Mild Phenotype 100.00 99.94 99.94 99.60 98.04 9.5.14 94.64 92.19 91.67 84.20 68.03 93.04 2.90 
Symptomatic 100.00 100.00 100.00 100.00 100.00 94.59 93.55 93.33 83.33 81.43 65.00 91.93 3.37 
C054 
Mild Phenotype 100.00 100.00 100.00 98.15 97.92 97.50 97.44 97.44 95.56 SS.OO 77.78 95.16 2.15 
%C03+/CD4-
Symptomatic 15.fiS 11.06 6.84 5.93 5.72 5.16 4.80 3.60 1.57 0.88 0.00 5.57 1.37 
CD69 
Mild Phenotype 19.09 6.77 6.28 6.00 4.52 4.25 3.SS 2.27 1.86 1.16 0.49 5.11 1.54 
%C03+/CD4+ 
Symptomatic 3.07 2.81 2.53 1.95 1.89 1.72 1.52 1.00 O.'}7 0.80 0.00 1.66 0.28 CD69 ' 
, Mild Phenotype 9.18 2.24 1.46 1.01 0.46 0.44 0.42 0.38 0.33 0.30 0.00 1.47 0.79 
5.4 DISCUSSION 
Published literature indicates that SeD patients that certain activation markers are 
expressed during periods of vasoocclusive crisis. Leukocytes interact with sickle 
erythrocytes and damaged endothelium layer through these activation markers and may 
contribute to vasoocclusion [19]. Hence, it is important to accurately determine the 
activation status and gene expression profile of the circulating cell populations in seD 
patients in order to realize and avert the onset of vasoocclusion. Interpretation of 
50 
activation status will be affected by sample preparation technique without cell loss and 
artifactual activation, significantly impacting the study. 
Data was first scored by percentage of a nucleated cell population according to phenotype 
marker in terms of total nucleated cells enriched by microfluidic lysis. Each population 
was then analyzed by activation markers and the percentage of the population exhibiting 
relative high activation was recorded. Markers for leukocytes and circulating endothelial 
cells were obtained from literature as the most widely used for each population in terms 
of phenotype and activation using flow cytometry [18, 29, 30]. Results comparing mild 
phenotype and symptomatic SCD patients have shown on average that no statistical 
difference exists based on percentage of nucleated cell populations and activation of these 
populations between the two groups, as shown in Figures 12-17. Rather, the percentages 
vary from among patients in each group, with coinciding upper and lower values, 
depicted in Tables 5-6. Although a statistical exception arises with CD62L on CDI4+ 
Monocytes (Figure 14), activation of this marker still notably varies among mild 
phenotype and symptomatic SCD patients (Table 6). 
Significance of these results can be interpreted in terms of patient-to-patient variation. 
Indeed, the percentage of circulating nucleated popUlations and their expression of 
activation markers extremely fluctuates among the population, healthy controls and SCD 
patients alike. Hence, due to such variability, one cannot definitively denote 
vasoocclusive crisis by simple analysis of expression markers. Epigenetic effects 
influenced by possibly mUltiple environmental factors may therefore be the primary 
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candidate for onset of crisis. Although all patients have the same genetic defect, heritable 
changes in the function of the gene occur without adjustments in the sequence 
(epigenetics). Such changes may influence the variability in expression among SeD 
patients. To render epigenetic effects on SeD one must first classify patients 
appropriately. 
Interrogating the immune status of an individual by staining for expression markers may 
yet prove valuable. The extreme variability in the data infers that the manner by which 
symptomatic seD patients are classified (mild phenotype or symptomatic) is too broad. 
Perhaps this system could be improved by categorizing seD patients by age group and 
specific symptoms (refer to Section 3.3) prior to placement in clinical studies. Until such 
classification IS imposed studies claiming to identify risk factors continue to be 
questionable. In conjunction with improving the classification of SeD patients, cell 
expression studies may in fact reveal markers or cell populations that playa role for 
particular groups of patients and possibly identify epigenetic effects. Such information 
could lead to more personal and specific therapies for seD rather than prescription of 
Common treatments. 
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CHAPTER VI - CONCLUSIONS 
6.1 CONCLUSIONS 
A micro fluidic device and enrichment protocol of circulating nucleated cells has been 
reported in this thesis. Superior performance in comparison to conventional enrichment 
techniques has been confirmed. In particular, the microfluidic protocol prevents cell loss 
and artifactual activation because of controlled exposure to harsh conditions. Further, the 
capability of this technique to generate clinically valuable information was also 
determined. The device, which allows for accurate analysis of the immune status of an 
individual, was used to study the disease process in patients with sickle cell trait. 
The first study in section 4 of the thesis compared healthy controls and mild phenotype 
SCD patients. Results from the study indicated a non-specific increase in all circulating 
nucleated cells, or no increase in any specific leukocyte population, and no activation in 
mild phenotype SCD compared to healthy controls. From this data it was concluded that 
mild phenotype patients are not in a state of chronic inflammation. Instead, these patients 
are in a highly favorable state for an inflammatory response due to an increased baseline 
leukocyte count, where a small stimulus could lead to activation of leukocytes and 
vasoocclusive crisis. Ultimately, the study established the baseline leukocyte counts and 
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activation status in mild phenotype SCD patients, data that can be used as a control for 
future studies seeking to evaluate SCD patients in pain crisis. 
The second study in section 5 compared mild phenotype and symptomatic SCD patients. 
Results from this study indicated that there is extreme variability in clinical expression 
among. individuals. Hence, it was concluded that one cannot definitively identify a single 
population or marker that indicates a vasoocclusive crisis. Rather, the system used to 
classify patients must first be revised in order to allow reports to discover risk factors in 
SCD. Overall, the study provides valuable information on the immune status of 
symptomatic SCD patients for evaluations seeking to measure severity of a vasoocclusive 
crisis. 
To sum up, a micro fluidic device has been developed and an enrichment protocol has 
been established. Changes in fluid behavior due to scaling effects have been exploited 
and manipulated. Processes have been achieved not feasible on the macro level. Indeed 
developments in technological aspects of the microfluidics field continue to prove 
invaluable. 
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CHAPTER VII - FUTURE DIRECTIONS 
7.1 FUTURE DIRECTIONS 
Several different paths exist for potential future projects with the microfluidic lysis 
device. In regards to Sickle cell disease (SCD) gene expression analyses can be carried 
out in conjunction with the lysis device to determine genetic risk factors responsible for 
the onset of a vasoocclusive crisis. These studies could provide further insight along with 
flow cytometry in the development for more specialized treatment of SCD. Other 
directions include investigating the role of circulating leukocytes in various diseases, 
automating the device, and cell sorting for analysis of unknown nucleated populations. 
7.1.1 DEVICE AUTOMATION 
As the efficacy of the microfluidic device has been exemplified in terms of clinical use 
and superiority to conventional techniques, the next step is complete device automation. 
To gain acceptance in the clinical or research field the protocol must be simplified. 
Hence, a platform can be developed eliminating user preparation steps and need for 
external machinery, such as syringe pumps. In other words one has to simply inject the 
blood sample and allow the apparatus to run. Below (Figure 18) is a representation of the 
proposed automation. Figures 18a and 18b depict the microfluidic lysis and sorting 
device in parallel with the fluids driven by a pressure source and a manifold with access 
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holes to encase the microfluidic device. Means to rid of centrifugation after lysis to 
separate out the nucleated cell populations via cell sorting is explained in the next 
subsection. 
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Figure 18: (a) Schematic representation of automated setup for leukocyte isolation. 
(b) Solid Edge model of manifold for fluidic interconnects to microfluidic lysis device. 
7.1.2 CELL SORTING 
Cell sorting allows populations to be separated by certain characteristics, a process that 
could eliminate centrifugation steps in the microfluidic lysis protocol. One distinguishing 
feature among nucleated cell populations and red blood cell debris is size. A device has 
been proposed in collaboration with Aman Russom, Center for Engineering in Medicine, 
Massachusetts General Hospital, Harvard Medical School, that separates particles based 
upon size utilizing Dean flow [31]. Particles experience transverse and longitudinal 
forces in a curved surface. Forming a ratio of these values (transverse flow -;- longitudinal 
flow) produces a dimensionless parameter, Dean's Number, that describes the outward 
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force felt by a particle [3]. Figure 19 depicts an AutoCAD drawing of the cell sorting 
device. Fluid enters from the center inlet via connecting tube from the lysis device. 
Particles exit through one of 6 ports based on size and mix with 2X PBS (outermost port) 
before exiting. Characterization of the sorter and combination with the lysis device would 
lead to an automated system. 
Figure 19. Schematic of proposed cell sorting device using Dean flow. 
Another characteristic of nucleated cells is mass density. Based on this property cells 
could be allowed to sediment within a microfluidic device. Employing theoretical values 
for cell sedimentation as a guideline, an experimental design to sort nucleated cell 
populations from red blood cell debris is possible, with flow rates determining time for 
sedimentation. In combination with the lysis device an automated system could be 
produced. 
7.1.3 ANALYSIS OF UNKNOWN CELL POPULATIONS 
Using the microfluidic lysis protocol to enrich nucleated cells, many interesting 
populations were found III the scatter plots not typically seen with conventional 
57 
techniques. Analysis of these unknown populations usmg flow cytometry or the 
aforementioned methods of cell sorting may lead to discovery of cell populations rarely 
seen in circulation. Ability to isolate and identify such populations may also lead to .' 
diagnosis of disease. 
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